During the American Society of Clinical Oncology (ASCO) conference in Chicago, researchers introduced several promising cancer treatments and insights. The experimental drug GRWD5769 can effectively expose tumor cells to the immune system, leading to significant tumor reduction in patients who had previously exhausted treatment options. In a remarkable breakthrough, the pill daraxonrasib doubled the survival time for patients with advanced pancreatic cancer, extending it to an average of 13.2 months compared to traditional chemotherapy. Additionally, the Optima trial demonstrated that genomic testing could allow many women with breast cancer to skip chemotherapy, marking a significant advance in personalized medicine. However, caution was expressed regarding the rising incidence of cancer, with experts warning of a potential workforce crisis in cancer care, predicting a shortage of 100 million professionals by 2050. The conference also highlighted the impact of lifestyle factors, such as sleep, on cancer risk, with studies indicating that poor sleep patterns may contribute to the increasing rates of early-onset cancers.